NCT03442569 2025-07-01
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
22 trialsNCT03428958 2025-04-23
A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
NuCana plc
Phase 1/2 Completed
NCT01814501 2025-02-05
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00788957 2024-08-07
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
NantBioScience, Inc.
Phase 1/2 Completed
NCT05468892 2024-02-01
VELO
University of Campania Luigi Vanvitelli
Phase 2 Completed
NCT00819780 2022-12-06
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Amgen
Phase 2 Completed
NCT00089635 2022-11-07
Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
Amgen
Phase 2 Completed
NCT01001377 2022-09-21
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
Amgen
Phase 3 Completed
NCT00389870 2022-06-01
Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil
University of Leeds
Phase 3 Completed
NCT00655499 2021-09-21
PIMABI
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Completed
NCT04342676 2020-04-13
Lymph Node Ratio and Kras Mutation in R Colon Cancer
Mansoura University
Phase 3 Completed
NCT00940316 2019-05-07
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Northwestern University
Phase 2 Completed
NCT00418938 2018-10-17
SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial
Amgen
Phase 2 Completed
NCT00332163 2016-02-23
STEPP
Amgen
Phase 2 Completed
NCT00411450 2016-02-15
PRECEPT
Amgen
Phase 2 Completed
NCT01108107 2015-05-21
Neoadjuvant Treatment of Colon Cancer
Vejle Hospital
Phase 2 Completed
NCT01358812 2015-03-11
TRIP
Gruppo Oncologico del Nord-Ovest
Phase 2 Completed
NCT00630786 2014-02-06
Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
Amgen
Phase 1/2 Completed
NCT00111774 2013-05-14
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
Amgen
Phase 2 Completed
NCT00004879 2013-01-08
Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT00039273 2013-01-08
Monoclonal Antibody Therapy in Treating Patients With Metastatic Colorectal Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00101894 2012-09-17
Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer
Amgen
Phase 1 Completed